Daiichi Sankyo Europe GmbH


    • Company type:
      • Manufacturer
      • Research & Development
      • Service Provider
    • Year founded:
    • 1899
    • Employees (at the site):
    • 300
    • Turnover range:
    • >=125m EUR
    • Products/services:
    • Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichi-sankyo.eu.

    • Core competencies:
    • hypertension, dyslipidemia, bacterial infections, thrombotic disorders, novel therapies in cardiovascular-metabolic diseases, pain management, oncology, including biologics

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 21: Manufacture of basic pharmaceutical products and pharmaceutical preparations
      • 21.2: Manufacture of pharmaceutical preparations
    • Certification:
    • not available

    • Sales markets - target industries:
    • Global, Europaweit
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Martin Hesse (Mr.)
      - Management

      Dr. Jan Van Ruymbeke (Mr.)
      - Management